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After the life sciences strategy: managing science-based R&D collaborations 
Notes from the event at NESTA, Friday 27 th January 2012 
A reminder: this event was conducted under the Chatham House rule, so remarks are not attributed 
to attendees or speakers. These notes form a summary of the main points of discussion from the 
various speakers and the questions. 
This event was supported by the Innovation Research Initiative that is funded by BIS, ESRC, NESTA 
and TSB (ESRC reference: RES-598-25-0032).  
Agenda 
10:00 – 10:05 Introduction – Louise Marston, Lead Policy Advisor at NESTA 
 10:05 – 10:20 Simcha Jong, UCL 
 10:20 – 10:50 Panel One: Transferring research from the lab and organizing R&D in start-up firms; 
 David T Phillips, Partner at SR One (The corporate venture capital arm of 
GlaxoSmithKline) 
 Harren Jhoti, President and founder of Astex Pharmaceuticals 
 John Sinden, CSO and founder of ReNeuron 
10:50 – 11:10  Questions for panel one 
11:10 – 11:40 Panel Two: Challenges in using R&D relationships with academic partners to enhance 
the firm’s innovative capabilities: 
 Dave Tapolczay, CEO of MRC Technology  
 Mike Wood, Director of R&D at Vernalis 
 Richard Storer, CSO of Summit Corporation.  
 11:40 – 12:00 Questions for panel two 
Main points and topics 
The industry environment is changing 
Large pharmaceutical companies are undergoing significant changes: restructuring R&D, reducing 
R&D budgets. Industry R&D is facing pressures to reduce costs, to identify return on their 
investments (ROI) and to reduce risk, especially risk of costly late-stage failure. 
A failure at Phase II is a catastrophic failure for a researcher that has spent years on the compound, 
but highly significant for the CEO as well – especially if it’s a blockbuster replacement. Pfizer lost 11% 
of its value, $12 billion, in a day when the failure of Torcetrapib at phase III was announced in 
December 2006. 
In the last 10 years or so, pharma has also become more like biotech in culture, somewhat more 
entrepreneurial and responsive to new technologies and opportunities. Some ideas which once 
would have spun out from large pharma can now be developed in-house.  
The changes in Big Pharma create opportunities to exploit, as well as challenges. If you’re looking to 
collaborate, you often never talk to the same person twice – reorganisations, site closures, and 
turnover of people all make it hard to maintain relationships. 
There was general approval from the speakers of the improvements in government infrastructure. 
NIHR and NOCRI are helpful and are making it easier to get R&D and regulatory approvals.  
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Technology Transfer Offices have broadly developed in the right direction. They used to be really 
difficult to deal with, and IP was always an issue. In the last 5 years or so, there have been a lot of 
new people added to those offices, and there has been a readjustment of thinking.  
Role of informal 
A lot of the good ideas that arrive at a large company are informally introduced – how can those 
informal touchpoints reach the right person to make a decision. How do we capitalise on the 
informal? 
To get things started, you need to encourage people to talk– forums for that are scarce. Meetings 
are important and are where many projects get started – but one of the first things to go when R&D 
gets cut is the travel budget.  
Some tech transfer offices and companies have a specialist team of people to make informal 
contacts in universities and research charities, both in the UK and overseas. Cutting travel makes it 
harder to make these informal contacts. There is a need for the R&D department to impress on 
Finance the importance of the informal, face-to-face contacts. Merck a few years ago appointed 500 
scientists as network agents, to go out and find interesting ideas. Glaxo used to have a milkround 
system where every university in the UK had a representative inside the company, and they got to 
know the research of that university in detail, giving access to lots of early-stage work. 
In the research phase, you might be more interested in serendipity, as opposed to venture funding 
and acquisition searches, which are more focused on a specific need. Ultimately, it means making 
the investment of time and money, putting it into people’s objectives, to make sure space is created 
for informal interactions.  
Responsiveness can also be an issue. Ideas can get squashed by lengthy committee processes. Small 
businesses have the advantage of being able to get things going in a few days, and are better able to 
keep the momentum going. It’s hard to get a quick answer from large companies –that’s not a 
criticism, just a fact. Taking away some of the approval process, and trusting in scientists to make 
good connections is a way to become more responsive to opportunities.   
There’s a fear that you’ll only have one good idea in your life – a fear about giving ideas away by 
sharing them. If you can get away from that fear you can co-operate with others to develop them. 
Great ideas only become great once a significant number of people have been involved in shaping 
them. You might need permission to get away from creating immediate value for the company, 
especially at a small company – that’s a very difficult thing to balance.  
Advantages of academic collaborations 
Most big pharma companies are not doing fundamental research in house any more. For example 
GSK had a hundred people sequencing genomes ten years ago. Not anymore. Failures in later stage 
trials can sometimes be traced to a lack of fundamental understanding of the pathways, or the 
absence of biomarkers to subdivide responders from non-responders. These are areas where the 
academic community can play an important role. 
There are also advantages for companies in engaging in academic collaborations: 
 It is easier to attract high-quality scientists to join a Scientific Advisory Board (SAB) if you 
have built up a scientific reputation. 
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 You have an advantage in recruiting PhDs that can amount to a 25% discount in hiring costs. 
In addition, publications act as an advertisement for the company. Allowing researchers 
inside the company to publish creates a scientific reputation for leading-edge science, as 
well as attracting people who read the papers to work for you. 
 Some translational grant funding, such as EU FP7, is easier to attract with a link to academic 
research. 
 Firms that publish have a higher R&D productivity over those that don’t. In fact, an analysis 
of the R&D productivity of UK biotechnology firms highlights that for each article firm 
scientists publish in a scientific journal, the firm typically enjoys a 5% jump in R&D 
productivity measured in terms of clinical compounds in the pipeline and a 9% jump in R&D 
productivity measured in terms of clinical compounds in the pipeline that are new chemical 
entities.  
 Making academic and university links both in the UK and overseas can also be important for 
funding. The National Cancer Institute (NCI) in the US and NCIC in Canada are sources of 
funding for oncology trials. 
Making academic and industry collaborations work 
Conducting research within the firm makes it easier to build links with academics. 
Different priorities, pressures and timescales can make direct collaboration between companies and 
academics fraught with tension. It’s important to recognise and then respect the different priorities 
and objectives that each side has, and to establish ground rules and expectations upfront. 
Working with industry won’t work for every academic – some need to focus on the blue sky 
research, and the teaching that are at the centre of universities. If you want to work together with 
academics, there is a need to be sensitive about the different environment academics work in. For 
example, trying to get academics to work on industry timescales is bound to lead to problems. 
Academic quality for regulators 
Academics generally don’t work under the same conditions that regulators require. To do this sort of 
work, you can try to put a quality system in place in the academic lab that will cover documentation, 
writing up procedures and address the need for auditable data required for regulatory submissions. 
Funders could get involved to advise on these systems. 
However, it may be that this work is better done within a company, rather than an academic lab: this 
is not always the best way to use their expertise. You are taking a bigger risk when you are reliant on 
the data coming out of academia for a regulatory submission. 
Sometime you might do work inside the company to support what the academic wants to do, where 
that is the most efficient way to make progress – in the same way you might use CROs. In this way, 
you use academic collaborations to push the boundaries of what you’re doing, rather than just an 
extended resource. Academics are looking for a new challenge in their collaborations –making a 
thousand analogues, for instance, would be a misuse of the academic’s time. 
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Timescales 
Small companies in particular have strict timelines to stick to, and little room for serendipity. 
Academics have an environment of licensing and committees for trials and research that can be slow 
for a small company. On the other hand, even when both parties are enthusiastic about 
collaboration, the time taken to negotiate the contract terms can mean a loss of momentum. 
Most academics are driven to be first to publish in competitive fields, and work hard to make sure 
they are at the cutting edge. Academics can be enthusiastic and keen to work to industrial 
timescales, but very few are able to focus all their time on your project, as you could inside a 
company or CRO. Managing collaborations alongside teaching duties, administration and other 
research is something few can achieve. 
Incentives for academics 
Academics do get incentives in the form of share options or shares in spin-out companies. 
Some technology transfer offices, such as Isis, market their academics as consultants, in which case 
they receive a consulting fee.  http://www.isis-innovation.com/consulting/  
The MRC runs a number of schemes for working in partnership with companies. These have a 35% 
success rate, compared to 20% for normal grant applications. 
The REF (Research Excellence Framework) now provides incentives to create impact – both social 
and economic – with research.  
It is important that we allow people to get on with blue skies research as well. There has to be 
significant effort on areas where the application or impact is very hard to see at the start. 
Technology transfer and licensing 
Technology transfer offices need highly professional people who can work with big companies. 
There are still pockets that are driven to bring in more short-term revenue (often from the vice 
chancellors office). Even if the academic is enthusiastic, if the TTO is unrealistic it may be best to 
stop the discussion early on, rather than try and persist.  
Industry also needs to be clearer to TTOs about what they are looking for. Hopefully they can then 
filter out much of the stuff that is not relevant. 
Spinning out 
It’s important to have someone on the team from an industrial background. They will bring a 
network that starts to build the personal connections for collaboration. You also need the 
experience of moving a programme from early stage to late-stage.   
Some other factors for success: 
 A clear shared vision across all of the team 
 A culture of collaboration that avoids knowledge silos 
 Choose and reward the best people but also reward appropriate risk taking 
 Balance fixed and variable costs – 80% internal, and 20% managed CROs outside. This gives 
you some flexibility to reduce external expenditure.  
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 Do no more than you can afford to do: don’t collect stamps – it’s tempting to get just one 
more piece of data. You may not need it. 
Funding for life sciences 
There is money out there for good companies. Imperial Innovations launched a £100m fund, GSK  
created a £50m UK fund. Good projects will find money at the end of the day. 
The single most important factor for UK biotech is a lack of appetite in the public markets in London 
for biotech stocks. Around 2004 the markets started to dislike research. Now they hate it, there is no 
interest in the research phase as adding value to the company. There is no simple answer but this is 
the single most important challenge.  
Charities can play a critical role in supporting research, through to trials – especially for rare or 
neglected diseases.  
Alternative sources of funding: R&D tax credits can be helpful, but can also make it difficult to get 
grant funding. It might not be cost-effective in terms of time or returns for a small company. 
SROne is considering putting a small amount of seed money into companies that aren’t yet 
commercially fundable to finance key experiments that they need to do, as well as providing some 
coaching and mentoring.  
Small companies working with academics 
Small companies without the clout of ‘big pharma’ aren’t able to enter into the long-term multi-
million dollar funding relationships that are becoming more popular with large companies. Instead, 
they need to pick small targeted pieces of work – a specific piece of data, access to patient samples 
or a particular technique. Doing these small pieces of targeted work quickly is quite hard because 
TTOs can still take a long time to get contracts signed. 
Small companies have a key position between academia and pharma, as pharma takes on more of a 
development role, with less focus on discovery. As mergers continue, and R&D groups get larger, 
spread across more sites it is hard to maintain relationships. This creates opportunities for small 
companies but also challenges – they still need funding to provide the bridge that advances early 
stage research and maintains the flow from academia into the marketplace. 
Links and further reading: 
Simcha Jong paper – Nature Biotechnology “Commercialising a disruptive technology” 
http://www.nature.com/bioent/2011/110601/full/bioe.2011.6.html  
"New modes of innovation" project webpage: http://www.esrc.ac.uk/my-esrc/grants/RES-598-25-
0032/read 
NIHR – National Institute of Health Research 
A special trust within the NHS charged with funding health research and infrastructure. 
http://www.nihr.ac.uk  
NOCRI – NIHR Office for Clinical Research Infrastructure 
An office set up to help public, charity and industry research funders work in partnership with NIHR 
infrastructure, including Biomedical Research Centres, and Units, facilities and networks. 
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http://www.nihr.ac.uk/infrastructure/Pages/nocri.aspx  
Translational Research Partnerships (formally Therapeutic Capability Clusters) 
These bring together investigators in the academic and NHS centres to support collaboration with 
industry in early and exploratory development of new drugs and other interventions. There are two 
partnerships currently running: Joint and related inflammatory diseases and Inflammatory 
respiratory disease. 
http://www.nihr.ac.uk/industry/Pages/translational_research_partnerships.aspx  
Christoph Westphal and Verastem: 
Serial entrepreneur and industry insider Christoph Westphal has recently led another IPO in the US. 
http://www.fiercebiotech.com/story/westphal-pulls-rare-stunt-55m-verastem-ipo/2012-01-27  
Survey of academics – 40% don’t want to be involved: 
http://www.timeshighereducation.co.uk/story.asp?sectioncode=26&storycode=418784&c=1  
“About 40 per cent of the researchers questioned who were working with the university to 
commercialise their work said they felt they had been "forced" to do so, Ms Miller told Times Higher 
Education. 
"They didn't really feel like it was part of their job - their job was teaching and research," she said, 
quoting one interviewee who said they "didn't know how to sell". 
GSK Academic superstars programme 
Dr Mark Pepys and Pentaxin: http://www.uclb.com/news/ucl-professor-mark-pepys-hailed-as-an-
academic-superstar-by-glaxosmithklineucl-professor-mark-pepys-hailed-as-an-academic-superstar-
by-glaxosmithkline  
MRCT – Development gap fund 
Pre-seed translational research fund for scientists in MRC units and institutes. Covers proof of 
concept studies, target validation components of drug discovery, assay development and 
device/diagnostic prototyping. Typical awards are £20-200k over two years, for salaries and 
consumables. 
http://www.mrctechnology.org/commercial-opportunities/funding-translation  
MRC Award To Inventor scheme  
A financial scheme where the researcher will receive a significant financial share in the IP. 
http://www.mrctechnology.org/information-for-researchers/protecting-your-ip/awards-to-
inventors 
MRC Fellowship scheme 
Encouraging placements with industry for a year to develop skills. 
http://www.mrc.ac.uk/Fundingopportunities/Fellowships/PEP/MRC006237  
